% | $
Quotes you view appear here for quick access.


markfive37 6 posts  |  Last Activity: Apr 20, 2016 12:17 PM Member since: Sep 19, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Biopharma group Geron Corporation (NASDAQ:GERN) unveiled positive findings from studies of its innovative cancer treatment imetelstat at a New Orleans conference.

    The first poster presentation revealed that treating acute myeloid leukemia (AML) cells with imetelstat enhanced the effects of agents currently used for treating the disease.

    The second showed results from non-clinical studies, which backed up findings of previous clinical trials, concerning blood platelet production.

    The work was presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting held in New Orleans, Louisiana.

    Imetelstat inhibits the activity of telomerase - an enzyme present in most types of cancer that enables tumor cells to replicate indefinitely.

    Imetelstat has not, as yet, been approved for marketing by any regulatory authority.

    The firm is developing the treatment under a collaboration agreement with Janssen Biotech, Inc.

    In late 2014, Geron entered an exclusive worldwide license and collaboration agreement with Janssen to develop and commercialize imetelstat for oncology, including hematologic myeloid malignancies, and all other human therapeutics uses.

    Under the terms, Geron received an upfront payment of $35 million and is eligible to receive additional payments up to a potential total of $900 million for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales.

    Certain regulatory, development, manufacturing and promotional activities are being managed through a joint governance structure, with Janssen responsible for these activities.

    Janssen is conducting two imetelstat clinical trials: a Phase 2 clinical trial in patients with intermediate-2 and high risk myelofibrosis (MF) and a Phase 2/3 clinical trial in patients with low and intermediate-1 risk myelodysplastic syndromes (MDS).

  • Reply to


    by ronbbck Apr 13, 2016 7:09 PM
    markfive37 markfive37 Apr 13, 2016 7:53 PM Flag

    ISIS on Wednesday put out a hit list targeting moderate Muslims — including top Hillary Clinton aide Huma Abedin.

    The list — in the latest edition of the terror group’s magazine Dabiq– targets several other prominent Muslims including US Rep. Keith Ellison of Minnesota and British pols Sayeeda Warsi and Sajid Javid.

    Abedin, the wife of former rep. Anthony Weiner, and other targets are branded “overt crusaders” and “politically active apostates,” who “involve themselves in the politics and enforcing laws of the kufr [disbelievers].”

    Clinton spokesman Glen Caplin told The Post he had no comment about ISIS’ hit list.

  • Reply to

    Illegals in the US

    by young_guns_dd Mar 22, 2016 6:32 PM
    markfive37 markfive37 Mar 22, 2016 10:03 PM Flag

    The official number of illegal aliens in the state of California is nearly 3 million. We can estimate the number to be more than double this amount in reality.

    Over half of all drivers license issued in California were given to individuals who are here illegally and the state automatically registers those with a driver’s license to vote.

    In 2015, California Governor Jerry Brown (D-CA) signed a bill giving full voting rights to illegal aliens. This gives them the right to vote in all elections from a local level to national elections, including that of choosing who will become President.

  • American Century Companies Inc. boosted its position in shares of Geron Co. (NASDAQ:GERN) by 22.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 687,621 shares of the biopharmaceutical company’s stock after buying an additional 126,770 shares during the period. American Century Companies Inc. owned 0.43% of Geron worth $3,328,000 as of its most recent filing with the SEC.
    Separately, California State Teachers Retirement System boosted its stake in shares of Geron by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 292,950 shares of the biopharmaceutical company’s stock worth $1,418,000 after buying an additional 5,223 shares during the last quarter.

  • Reply to

    Trump's father and the K__k,k

    by weghox403 Mar 14, 2016 1:31 PM
    markfive37 markfive37 Mar 18, 2016 12:16 PM Flag

    Hillary Clinton can add a new name to her list of endorsements ? a prominent #$%$ member who says he likes her because of her "hidden agenda."

    Will Quigg, a grand dragon of the #$%$'s California chapter, told the Telegraph Monday that he would be switching his support from Donald Trump to Clinton.

  • markfive37 markfive37 Mar 14, 2016 6:39 PM Flag

    Trump will likely win because Lincoln was right............You cant fool all the people all the time. The masses have caught on to what has been going on for the last 12 plus years